Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bio-Gene Technology’s (BGT) insecticides could soon be used in mosquito control across North, Central and South America
  • The agtech developer has partnered with Clarke Mosquito Control to further develop formulations of Bio-Gene’s Flavocide and Qcide technologies
  • The partnership follows Clarke’s successful internal testing of the technologies on three different types of mosquitoes
  • Company shares are trading flat for 19.5 cents each

Bio-Gene Technology’s (BGT) insecticides could soon be used in mosquito control across North, Central and South America.

The agtech developer has today announced a partnership with Clarke Mosquito Control to further develop its Flavocide and Qcide technologies.

In August 2019, Bio-Gene signed a Material Transfer Agreement (MTA) with Clarke which allowed Clarke to undertake internal testing of the technologies on Anopheles, Aedes and Culex mosquito species.

Following successful results from the internal testing, Clarke and Bio-Gene inked the agreement which will see them further develop the formulations of Flavocide and Qcide.

Bio-Gene CEO and Managing Director Richard Jagger said the partnership represents a significant milestone for the company.

“This agreement with Clarke has the opportunity to expand into other markets and is very valuable for our discussions with other stakeholders including, for example, NGOs and philanthropists to further develop commercialisation opportunities in the public health space,” he commented.

At present Bio-Gene is in discussions with other companies, seven of which are carrying out their own testing on Flavocide and Qcide under MTAs. These companies work in crop protection, grain storage, public health and consumer products.

Company shares are trading flat for 19.5 cents each at 12:56 pm AEST.

BGT by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…